The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Loxo; Merck; Nektar; Tesaro
Research Funding - Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; Takeda; Tesaro
KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.
 
David Qian
No Relationships to Disclose
 
Madhusmita Behera
No Relationships to Disclose
 
Conor Ernst Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; BerGenBio; Lilly
Research Funding - Daiichi Sankyo; Infinity Pharmaceuticals; Seagen; Vaccinex
 
Suchita Pakkala
Consulting or Advisory Role - ARIAD
 
Jennifer W Carlisle
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Benjamin Walker Fischer-Valuck
No Relationships to Disclose
 
Aparna Hemant Kesarwala
No Relationships to Disclose
 
Jeffrey Bradley
Consulting or Advisory Role - AstraZeneca
 
Walter J Curran
Honoraria - AstraZeneca
Consulting or Advisory Role - Varian Medical Systems; Vertex
Research Funding - Abbvie (Inst)
 
Suresh S. Ramalingam
No Relationships to Disclose
 
Kristin Ann Higgins
Consulting or Advisory Role - AstraZeneca; Genentech; Varian Medical Systems
Speakers' Bureau - AstraZeneca
Research Funding - Reflexion Medical